Bnp Paribas Asset Management Holding S.A. Cerevel Therapeutics Holdings, Inc. Transaction History

Bnp Paribas Asset Management Holding S.A.

  • $38.7 Billion
  • Q2 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 09, 2024
SELL
$20.27 - $42.44 $3.71 Million - $7.76 Million
-182,826 Reduced 32.64%
377,329 $16 Million
Q3 2023

Nov 13, 2023
BUY
$20.26 - $31.91 $3.25 Million - $5.11 Million
160,287 Added 40.08%
560,155 $12.2 Million
Q2 2023

Aug 08, 2023
SELL
$23.9 - $35.38 $500,107 - $740,326
-20,925 Reduced 4.97%
399,868 $12.7 Million
Q1 2023

May 08, 2023
BUY
$22.82 - $35.32 $9.6 Million - $14.9 Million
420,793 New
420,793 $10.3 Million

Others Institutions Holding CERE

# of Institutions
242
Shares Held
154M
Call Options Held
2.19M
Put Options Held
3.87M
View Full List

About Cerevel Therapeutics Holdings, Inc.

CERE Quotes by TradingView
  • Ticker CERE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 155,752,000
  • Description
  • Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...
More about CERE
Track This Portfolio

Track Bnp Paribas Asset Management Holding S.A. Portfolio

Follow Bnp Paribas Asset Management Holding S.A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bnp Paribas Asset Management Holding S.A., based on Form 13F filings with the SEC.

News

Stay updated on Bnp Paribas Asset Management Holding S.A. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email